Menon’s team pessimistic on Brexit ‘no deal’

The team behind the ESRC’s ‘UK in a Changing Europe’ project has reiterated the risks of failing to reach a trade deal with the EU.

In the project’s report, Cost of No Deal, published on 20 July, principal investigator Anand Menon of King’s College London and colleagues argue that pharmaceutical research in the UK would suffer immediate impact with large companies potentially moving some or all of their research and development activities abroad.

According to the report, international clinical trials currently in progress would also be “adversely impacted”.